To mitigate risks, investors should diversify their portfolios across different stages of development and types of cancer treatments. Due diligence, including thorough analysis of clinical data and regulatory pathways, is crucial. Engaging with experts and consultants who have a deep understanding of the oncology landscape can also provide valuable insights.
